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INTRODUCTION
Since 2010, the American Association of Clinical 
Endocrinologists-Associazione Medici Endocrinologi-
European Thyroid Association (AACE-AME-ETA) guidelines 
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Objective: While many studies have reported that laser ablation (LA) for benign non-fuctioning thyroid nodules is 
efficacious in reducing nodular volume and neck symptoms, none have described changes in quality of life (QoL). The 
purpose of this study was to report post-LA changes in QoL in our cohort of patients.
Materials and Methods: Fourteen patients with benign thyroid nodules were involved in a prospective, single-center study 
and underwent a single session of LA. We evaluated the following: changes in nodule volume, thyroid function, and 
autoimmunity; adverse events during and after LA; changes in neck discomfort by means of a visual analogic scale (VAS) at 
one week and 1, 3, 6, and 12 months; and changes in QoL through the 13-scale Thyroid-specific Patient Reported Outcome 
(ThyPRO) questionnaire at 1, 3, 6, and 12 months. ThyPRO is a validated questionnaire for thyroid diseases, which consists 
of 13 scales with multiple-choice answers. They investigate several aspects of life that may be impaired by goiter-related 
compression symptoms, by esthetic alterations and by hypo- or hyperthyroidism.
Results: Nodule volume decrease was -37 ± 23%, -55 ± 22%, -53 ± 25%, -58 ± 25% (p < 0.01 vs. baseline) at the first, 
third, sixth, and twelfth month, respectively. No hypothyroidism or positivization of autoimmunity was observed. There 
were no major complications during or after LA. After LA, VAS scores improved significantly from 1 week onwards in 100% 
of patients, while a significant improvement was seen in the goiter symptoms score after one month, and in the general 
score and mean values of ThyPRO after six months. Scores on the other ThyPRO scales did not change significantly.
Conclusion: Laser ablation is safe and effective in reducing nodule volume and neck symptoms; this is confirmed by 
improvements in the goiter scale, general score, and mean values of ThyPRO and in the VAS score.
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have recommended laser ablation (LA) as a possible 
therapeutic option for the treatment of benign symptomatic 
thyroid nodules in patients who refuse thyroidectomy, or in 
those with comorbidities that contraindicate surgery (1). 
LA tends to be less expensive than thyroidectomy, whether 
total or partial. LA also does not require hospitalization, 
and causes only mild and rare adverse events. Thus, it can 
be undertaken in patients with contraindications for surgery 
or in those who refuse surgery. Moreover, compared with 
surgery, minimally invasive procedures for benign thyroid 
nodules preserve normal thyroid function (2).
Other non-surgical treatments for benign thyroid nodules 
include other percutaneous techniques, such as ethanol 
ablation, microwave or radiofrequency, and high-intensity 
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focused ultrasound (3). LA, radiofrequency ablation (RFA), 
and ethanol ablation are also utilized for recurrent thyroid 
cancer (3).
Other non-invasive techniques for reducing benign 
thyroid nodules are radioiodine with recombinant thyroid-
stimulating hormone (TSH) (4) or suppressive levothyroxine 
(L-T4) therapy (5). 
While many studies have reported reductions in treated 
nodules and improvements in the sense of pressure and 
in esthetic symptoms (3) after LA, none have described 
changes in quality of life (QoL). The aim of our study was 
to therefore evaluate QoL changes in a cohort of patients 
treated with a single session of LA for benign thyroid 
nodules. 
MATERIALS AND METHODS
We conducted this prospective single-center study at 
the endocrinology department of IRCSS AOU San Martino 
University-IST of Genoa (Italy) from September 2014 to 
September 2015. All patients signed an informed consent 
form that included a detailed explanation of the LA 
procedure and its purpose. Our Ethics Committee approved 
the LA treatment protocol.
Subjects
We evaluated patients with benign thyroid nodules, 
solid or nearly completely solid (with a liquid component 
not exceeding 30%), single or clearly detectable in a 
multinodular goiter, with a view to undergoing percutaneous 
LA (3). These patients had either refused total or subtotal 
thyroidectomy, or had comorbidities that contraindicated 
surgery. 
We enrolled 14 patients (12 females and 2 males) aged 
between 38 and 72 years (mean ± standard deviation [SD], 
55 ± 10 years) with a single thyroid nodule (n = 8, 57%) 
or a predominant thyroid nodule in a goiter (n = 6, 43%). 
These nodules, which had been discovered 7 ± 8 years 
earlier, were located in the right lobe in 10 patients (71%) 
and in the left lobe in six patients (29%). No patient had 
undergone ethanol ablation of the nodule or radioiodine 
therapy. Two patients were on L-T4 replacement therapy for 
hypothyroidism at a mean dosage of 616 ± 124 μg/weekly. 
Table 1 reports on patients’ features.
Pre-Ablation Assessment and Protocol
Before performing LA, we excluded contraindications for 
the procedures, as recommended in the Consensus Statement 
of the Korean Society of Thyroid Radiology for RFA (6). 
Before LA, patients underwent the following: a review 
of clinical data and physical examination; routine blood 
tests and thyroid function tests (free T3 [f-T3], free T4 [f-
T4]; TSH); evaluation of anti-thyroid peroxidase antibodies 
(TPOAbs), calcitonin, thyroglobulin, electrocardiography; 
and a phoniatric examination. We evaluated the volume 
(mL) of the nodule undergoing LA by means of the ellipsoid 
formula: antero-posterior diameter x latero-lateral diameter 
x cranio-caudal diameter in millimeter (mm) x 0.52 / 1000. 
We also used this formula to calculate the total volume of 
each thyroid lobe (7).
Before LA, patients underwent fine needle aspiration of 
the nodule on two separate occasions, to confirm benignity 
cytologically (Thy 2 in accordance with the British Thyroid 
Association (8)). Only patients with a finding of benignity 
on both occasions underwent LA. 
Patients filled out both a symptomatic visual analogic 
scale (VAS) that rated discomfort in the neck and a 13-scale 
Thyroid-specific Patient Reported Outcome (ThyPRO) QoL 
questionnaire validated for patients with thyroid disease (9).
Clinical examinations, assessments of thyroid function 
and thyroid autoimmunity, and VAS scores were repeated 
after one week and 1, 3, 6, and 12 months. ThyPRO and 
ultrasound thyroid volume were evaluated after 1, 3, 6, and 
12 months. We performed follow-up ultrasound examinations 
using a MyLab Five (Esaote®, Genoa, Italy) ultrasound 
scanner with a 7.5 MHz linear transducer (LA 523, Esaote®). 
We repeated phoniatric examination if symptoms related to 
chordal dysmotility appeared after the procedure. 
Procedures and Methods
Laser ablation was performed in an out-patient regimen. 
Antiplatelet and anticoagulant therapies were suspended 
a week before the procedure. On the day of the procedure, 
patients were in a state of 8-hour fasting. After placement 
Table 1. Patients Demographic Data
Males/Females   2/12
Age (years) (mean ± SD)   55 ± 10
BMI (kg/m2) (mean ± SD) 25 ± 4
L-T4 therapy (yes/no)   2/12
Time since diagnosis (years) (mean ± SD)   7 ± 8
MNG/UNG   6/8
Location of the nodule (right lobe/left lobe) 10/6
BMI = body mass index, L-T4 = levothyroxine, MNG= multinodular 
goiter, SD = standard deviation, UNG= uninodular goiter
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of a venous catheter, patients underwent intravenous 
infusion for over 30 minutes of ketorolac 20 mg (Tora-dol®, 
Recordati Spa, 10 mg/mL, Milan, Italy) and ranitidine 50 mg 
(Ranitidina®, 50 mg/5mL, S.A.L.F. Spa, Cenate Sotto, Italy) 
diluted in 100 mL of 0.9% saline solution. Subsequently, 
intravenous ketorolac 40 mg (Tora-dol® Recordati Spa, 10 
mg/mL) and ranitidine 50 mg (Ranitidina® 50 mg/5 mL, 
S.A.L.F Spa) were administered in 500 mL of 0.9% saline for 
about five hours (during and after LA). In subjects allergic 
to ketorolac or in patients with moderate-to-severe renal 
impairment, premedication with intravenous paracetamol 
(500 mg) (Perfalgan®, 10 mg/mL, 50 mL, Bristol-Myers 
Squibb Srl, Roma, Italy) was carried out before and during 
the procedure. We placed patients on an operating table in 
the supine position with the neck hyperextended. Before 
LA, we performed a careful US examination to evaluate neck 
anatomy and ensure preservation of the “danger triangle” 
during procedures (10). Local anesthesia with 2% lidocaine 
(Lidocaina Cloridrato®, 20 mg/mL, Monico Spa, Mestre, 
Italy) was carried out at the puncture site. If the patient 
did not tolerate pain during ablation, we reduced the power 
or turned it off for several seconds. 
In three patients, we performed percutaneous drainage 
of cystic intranodular fluid before the procedure. LA was 
performed in a single session by a single operator. The 
operator had one year of experience with LA, four years 
of experience of thyroid RFA, and 22 years of experience 
with fine-needle aspiration biopsy, by means of 300 μm 
diameter fibers and a 21-Gauge Chiba-needle (ELESTA®, 
Calenzano, Italy). Procedures were performed by means 
of a commercially available US scanner (Echo-laser X4®, 
Esaote®) equipped with a 7.5 MHz linear transducer (LA 
332, Esaote®) with a 1064 μm diode laser unit with a 
maximum of four laser sources, each with an individual 
energy emission setting and independent activation. 
The operator was positioned at the patient’s side and 
inserted from one to two fibers into the longitudinal length 
of the nodule, forming a shape matching the ellipsoid 
of thyroid nodule. The initial energy was delivered at 
1200–1800 Joules per fiber with an output power of 2−4 W, 
starting at one centimeter from the bottom of the lesion. 
One or two 1-cm pull-backs were programmed to maximize 
the ablation volume in a single LA session. The number of 
fibers, their placement, the number of pull-backs and total 
energy delivered were tailored to the shape and volume of 
each thyroid nodule, as described by Baek et al. (11). LA 
lasted 16 ± 2 minutes on average (range: 13−19 minutes), 
with a mean delivery of 4459 ± 1525 J (range: 1713−6203 
J), one or two fibers (mean 1.7) and one or two pull-backs 
(mean 1.3). The energy load in J/mL was 340 ± 196 (range: 
87−742 J/mL). Light irradiation was continuous, but was 
suspended in the event of pain or in order to reposition the 
fibers.
After LA, patients received a compressive bandage and 
ice to apply to the neck. Patients were allowed a light meal 
before being discharged in the early afternoon. All subjects 
received a domiciliary prescription for steroid administration 
(prednisone 25 mg for three days, 12.5 mg for three days, 
6.25 mg for three days) and gastric protection, if not 
already ongoing.
Laboratory Tests
We measured TSH, f-T3, and f-T4 by ultra-sensitive 
chemiluminescence immunoassay (Cobas® e602, Roche 
Diagnostics, Milan, Italy). The normal ranges are: 0.27−4.2 
mIU/L for TSH, and 2.76−7.07 pmol/L and 11.97−21.88 
pmol/L for f-T3 and f-T4. We evaluated TPOAbs by means 
of DiaSorin (Saluggia, Italy); we regarded concentrations 
< 100 mU/L as negative. We measured calcitonin by 
chemiluminescence immunoassay (DiaSorin); in our 
laboratory, the normal value is < 10 ng/L. We performed 
automated complete blood counts using an ADVIA 2120 
automated counter (Siemens Healthcare, Milan, Italy); 
coagulation tests on an automated BCS analyzer (Siemens 
Healthcare); and biochemical tests for the routine 
assessment of hepatic and renal function on the fully-
automated Cobas® c701 platform (Roche Diagnostics).
Questionnaires
We evaluated the subjective benefits of LA several 
times during the study through a VAS with a score ranging 
from 0 (no symptoms/discomfort) to 10 (highest level 
of symptoms/discomfort). We assessed QoL before the 
procedure (baseline), and after 1, 3, 6, and 12 months, 
by means of ThyPRO, a validated questionnaire for thyroid 
diseases (9), which consists of 13 scales with multiple-
choice answers (0 = “none”; 1 = “slight”; 2 = “moderate”; 3 
= “severe”; 4 = “very severe”). The ThyPRO scales concern 
the following aspects: goiter symptoms, hyperthyroid 
symptoms, hypothyroid symptoms, eye symptoms, tiredness, 
cognitive problems, anxiety, depression, emotional 
susceptibility, impaired social life, impaired daily life, 
impaired sex life, and cosmetic complaints.
We also evaluated a further scale, dubbed “general score.” 
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It assesses answers to the question, “In the last 4 weeks, 
has thyroid disease had a negative effect on your QoL?” 
Lastly, we considered the mean values of the 13-scale score 
(9). 
Statistical Analysis
We present continuous data as means ± SD. We analysed 
all data by the GraphPad Prism for Windows (version 6.0, 
GraphPad Software, San Diego, CA, USA), by means of a 
non-parametric test. We assessed correlations between 
variables by means of the Spearman correlation. A p value < 
0.05 indicated significance.
RESULTS
Procedure Effects
On enrolment, the mean volume of the nodules was 19 
± 14 mL (range: 5−55 mL) and the total gland volume was 
32 ± 16 mL (range: 13−59 mL). Table 2 reports the mean 
volume of nodules and thyroid at each time-point of the 
study. Figure 1 reports on the mean volumetric changes at 
different time-points. 
After LA, we found a progressive reduction in nodule 
volume: -37 ± 23%, -55 ± 22%, -53 ± 25%, -58 ± 25% at 
the first, third, sixth and twelfth month, respectively (p < 
0.01 vs. baseline at the first, third, and sixth month, and 
p < 0.05 at the twelfth month). The percentage reductions 
in thyroid volume were significant at 3, 6, and 12 months 
(p < 0.01, < 0.05, < 0.05, respectively) (Fig. 1). At the 
12-month follow-up, we observed a reduction of > 50% in 
86% of the patients treated (p < 0.01). In two patients 
(14%), however, LA resulted in a nodule volume reduction 
of < 20%.
Figure 2 shows a nodule at the baseline of the study (Fig. 
2A) and the same nodule 12 months after LA (Fig. 2B).
Changes in Thyroid Parameters 
Table 3 depicts the parameters of thyroid function at 
the baseline and at the various time-points. f-T4, f-T3, 
thyroglobulin, and TSH levels did not exhibit significant 
changes (Table 3). None of the patients developed 
hypothyroidism. None of the subjects on L-T4 therapy on 
enrolment had to increase the dosage. TPOAbs were positive 
in 21% of patients (n = 3); this percentage was the same at 
Table 2. Volume of Nodules and Thyroid (Mean ± SD) and Volume Reduction Ratio of Nodules and Thyroid at Each Time-Point of 
Study
Time of Study Nodule Volume (mL) 
Nodule Volume  
Reduction Ratio (%)
Thyroid Volume (mL)
Thyroid Volume  
Reduction Ratio (%)
Baseline   19 ± 14 - 32 ± 16 -
1st month 11 ± 9 -42 28 ± 13 -12
3rd month    9 ± 10 -57 23 ± 11 -28
6th month  10 ± 11 -47 24 ± 12 -25
12th month   9 ± 12 -57 24 ± 13 -25
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Fig. 1. Mean changes (columns) with SD (error bars) in nodule (full columns) and thyroid (empty columns) volume in milliliters 
(A) and percentage (B). Significance vs. baseline: *p < 0.05, **p < 0.01. SD = standard deviation
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the last evaluation. 
Subjective Complaints 
During the procedure, four patients (26%) experienced 
discomfort in the neck, and three patients (21%) 
experienced pain. Seven patients (50%) did not experience 
any problems. One week after the procedure, five patients 
(36%) did not have any problems, four (26%) felt 
discomfort in the neck, three (21%) felt pain (mean VAS 
score was 3 ± 2), three (21%) had edema in the neck 
and one (7%) had a hematoma. These symptoms did not 
require any kind of medication and resolved spontaneously 
during the first month. No patient developed hoarseness, 
dysphagia, nodule rupture, major bleeding or infections. 
The VAS score at the baseline was 5 ± 3, and was 
significantly lower at each subsequent evaluation: from 
the first week after LA until the last evaluation at the 
twelfth month (Fig. 3). The VAS score improved in 100% of 
patients. 
Table 4 shows the mean score on each ThyPRO scale at 
Table 3. Thyroid Function at Each Time-Point of Study (Mean ± SD)
Time of Study TSH (mIU/L) f-T3 (pmol/L) f-T4 (pmol/L) Thyroglobulin (μg/L)
Baseline 1.76 ± 1.31 5.07 ± 0.74 14.69 ± 2.40 104.9 ± 83.5
1st week 1.33 ± 0.97 5.24 ± 0.63 15.30 ± 1.80 452.2 ± 658.8
1st month 1.25 ± 0.85 5.24 ± 0.55 14.95 ± 2.28 99.8 ± 93.7
3rd month 1.28 ± 1.30 5.42 ± 0.54 15.37 ± 2.11 103.9 ± 228.9
6th month 1.57 ± 1.29 5.07 ± 0.72 14.97 ± 1.71 107.9 ± 178.0
12th month 1.07 ± 0.55 5.01 ± 0.64 15.24 ± 2.11 73.0 ± 57.8
f-T3 = free T3, f-T4 = free T4, TSH = thyroid-stimulating hormone
A
C
B
D
Fig. 2. Changes in volume of nodule at ultrasound scan at baseline (A, B), 12 months after LA (C, D). Transverse (A, C) and 
longitudinal images (B, D).
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each time-point of the study. The data shows a significant 
improvement on the scale of “goiter symptoms” from the 
first month onwards, and on the scale of “general score” 
from the sixth month onwards. The mean values of the 13 
scales also improved significantly from the sixth month 
onwards (Fig. 4). These improvements persisted over time. 
By contrast, no significant changes in the other scales were 
recorded. 
DISCUSSION
The present paper reports our preliminary data on the use 
of a single session of LA to treat 14 benign thyroid nodules 
in 14 patients recruited over 12 months and followed up for 
12 months.
We used standard procedures recommended by the Korean 
RFA Guidelines (7, 11), and we performed LA after excluding 
contraindications. 
The mean reduction in the volume of our nodules appears 
to be similar or slightly lower than those observed in other 
centers: 58 ± 25%. At 12 months, the mean nodule volume 
reduction was -72 ± 11% in a study by Pacella et al. (12), 
-84 ± 13% in a study by Achille et al. (13), -59 ± 22% 
in a study by Papini et al. (14), - 51 ± 11% in a study by 
Døssing et al. (15), and -70 ± 16% in a study by Mauri et 
al. (16).
The mean reduction in the volume of our nodules appears 
to be similar or slightly lower than that observed after a 
single session of RFA: -74 ± 12% in a study by Mauri et al. 
(16), -69 ± 14% in a study by Cesareo et al. (17), and 77 ± 
3% in a study by Faggiano et al. (18), -79.7%  in a  study 
of Baek et al. (19), -84 ± 15% in a study of Jeong et al. (20). 
We achieved more than 50% volume reduction at the 12 
months in 86% of nodules. This result is comparable to, or 
better than, the data presented in a three-year multicenter 
prospective study (67.3%) (14).
Laser ablation can lead to normalization of TSH in 
patients with hyperthyroidism with “hot” nodules (21). 
The literature reports a change in thyroid function (hypo- 
or hyperthyroidism) in 2% of patients after LA (12). By 
comparison, in our study that enrolled only euthyroid 
patients, LA did not lead to significant changes in thyroid 
function and preserved euthyroidism. This data confirms 
the safety of this procedure and may prompt percutaneous 
Table 4. Thyroid-Specific Patient Reported Outcome Scores (Mean ± SD) on Each Scale at Each Time-Point of Study
Scales Baseline 1st month 3rd month 6th month 12th month
Goiter symptoms 23 ± 13 10 ± 8*   9 ± 9**   8 ± 5**   7 ± 4**
Hyperthyroidism symptoms 13 ± 14   8 ± 14   9 ± 14   8 ± 9   2 ± 3
Hypothyroidism symptoms   9 ± 9   6 ± 6   8 ± 9   9 ± 10   7 ± 4
Eye symptoms   9 ± 9   5 ± 7   6 ± 9   3 ± 5   1 ± 2
Tiredness 34 ± 13 32 ± 13 31 ± 16 26 ± 10 21 ± 5
Cognitive problems 11 ± 13   7 ± 12 13 ± 12 10 ± 8   6 ± 4
Anxiety 17 ± 13 12 ± 11 13 ± 17 18 ± 13 17 ± 7
Depression 26 ± 15 19 ± 12 23 ± 15 17 ± 14 19 ± 9
Emotional susceptibility 20 ± 17 15 ± 13 14 ± 18 12 ± 10 10 ± 4
Impaired social life   3 ± 5   5 ± 9   3 ± 6   0 ± 2   0 ± 0
Impaired daily life   5 ± 10   6 ± 8   4 ± 10   2 ± 4   0 ± 0
Impaired sex life   6 ± 11   4 ± 8   3 ± 6   1 ± 4   3 ± 6
Cosmetic complaints   6 ± 8   6 ± 11   4 ± 8   2 ± 4   1 ± 3
General score 14 ± 19   7 ± 12   4 ± 13   0 ± 0**   0 ± 0*
Mean values 14 ± 7 10 ± 7 11 ± 9   9 ± 5*   7 ± 1*
*p < 0.05 vs. baseline, **p < 0.01 vs. baseline
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**p < 0.01
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techniques to be preferred to surgery, which causes 
hypothyroidism in 100% of cases after total thyroidectomy 
and in 22% of cases after hemithyroidectomy (2). In 
comparison studies between RFA and surgery, there were 
also no hypothyroidism patients after RFA (22, 23).
Most of our patients did not experience any problems 
either during or after LA. In our study, adverse events were 
few and mild; indeed, the main complaints were “discomfort 
in the neck” and “pain” during and after LA. If these 
symptoms started after LA, they resolved spontaneously in 
a few weeks; if they arose during LA, they were alleviated 
by reducing the energy delivered or turning off the fibers 
for several seconds. In any case, pain was mild, with the 
mean VAS score being 3. 
Other adverse events in our experience were 
asymptomatic edema of the neck in one patient and a 
superficial hematoma in another patient; however, these 
resolved spontaneously. Our patients did not suffer other 
major adverse events, such as dysphagia, nodule rupture, 
pericapsular bleeding, vagal symptoms with bradycardia, 
or infections, which were reported in 0.5% of cases in a 
study by Pacella et al. (12) on 1280 nodules treated with 
LA. In that study, the rate of major complications was 
lower in patients treated without local anesthesia or with 
no conscious sedation than in patients managed with local 
anesthesia and conscious sedation. Conversely, complaints 
of side effects were more frequent in subjects treated 
without local anesthesia (12). In our protocol, we did not 
use conscious sedation, which probably explains why we 
observed no major complications and few adverse events. 
In our cohort of patients, we did not administer local sub-
capsular anesthesia, but subcutaneous tissue anesthesia. 
Furthermore, we infused analgesic and anti-inflammatory 
drugs before and during the procedures and prescribed 
steroids for some days after discharge, in order to minimize 
complications. While these precautions probably helped to 
minimize complications, they did not completely alleviate 
pain and discomfort in the neck. 
It should be borne in mind that proximity of the light 
to the capsule cause pain and discomfort in the neck. If 
patients complain of these symptoms during the procedure, 
the patients can thereby help the operator not to exceed 
the capsule of the treated nodule and minimize adverse 
events (12). In any case, the complications of LA, and 
of other minimally invasive procedures, such as RFAs 
(11), are fewer and milder than those of thyrodectomy, 
whether total or partial. The types and frequencies of 
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A. Goiter symptoms scale. B. General score scale. C. Mean values. 
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adverse events of thyroid surgery are described in a recent 
review by a group of Indian surgeons (24). A study by 
Wang et al. (25) describes the prevalence of complications 
after conventional and endoscopic thyroidectomies as 
follows: transient laryngeal nerve palsy in 5.4%, transient 
hypocalcemia in 3.6%, bleeding in 0.5% and hematoma 
in 0.5% of cases. Furthermore, discomfort in the neck and 
chest was reported in 80% of patients on the third day, and 
pain in the neck and chest in 10% of patients one month 
after thyroidectomy (25).    
Many studies have reported improvements in neck 
discomfort and esthetic symptoms after LA. In a study by 
Valcavi et al. (21), neck symptoms improved in 73% of 
patients, were unchanged in 23%, and worsened in only 
4%; esthetic symptoms improved in 71% of patients, were 
unchanged in 24%, and worsened in 5%. Moreover, in 
a study by Pacella et al. (12), neck symptoms improved 
in 10−49% of cases, and esthetic symptoms improved in 
8−86% of cases. In addition, in a study by Achille et al. 
(13), esthetic problems were completely resolved in 87% of 
treated patients, reduced in 9%, and unchanged in 2%, and 
pressure symptoms were resolved in 88% of cases. In our 
study, esthetic complaints were assessed by means of the 
cosmetic scale of ThyPRO, which revealed no improvement 
after LA. However, it should be noted that the baseline 
scores on this scale were very low in all our patients. 
Quality of life is defined as a person’s perception of his/
her position in life, in the context of the culture and system 
of values in which he or she lives and in relation to his or 
her objectives, expectations, standards, and concerns (26). 
In thyroid diseases, besides ThyPRO, QoL is often calculated 
by means of various questionnaires: the Short Form-36 (27), 
the SF-12 Health Survey (28), the Hamilton Depressive 
Scale (29), and the Kellner Symptoms Questionnaire (9, 30). 
While the Hamilton Depressive Scale (24-scale 
multiple-choice questionnaire) and the Kellner Symptoms 
Questionnaire (92-item questionnaire with Yes/No answers) 
focus more on the psychological aspects of QoL, the Short 
Form-36 (11-scale multiple-choice questionnaire), the 
slimmer SF-12 Heath Survey (12-item multiple-choice 
questionnaire), and ThyPRO analyze both physical and 
mental health (9, 27-30). We chose to utilize ThyPRO 
because it has been validated for thyroid diseases and 
could therefore provide a more detailed analysis of QoL 
in patients undergoing thyroid LA. Indeed, the 13 scales 
of ThyPRO investigate several aspects of life that may 
be impaired by goiter-related compression symptoms or 
discomfort in the neck, by esthetic alterations and by an 
altered thyroid function (both hypo- and hyper-thyroidism). 
As of this writing, no literature has reported on changes 
in QoL in patients treated with LA. However, ThyPRO has 
been used to assess QoL in numerous benign and malignant 
thyroid diseases. Regarding the use of questionnaires to 
evaluate changes in QoL in patients treated with thermal 
ablation for thyroid nodules, a study by Valcavi et al. (31) 
reported a significant improvement in QoL. The study 
assessed QoL using the Physical Component Summary and 
Mental Component Summary of Short Form-12 after two 
years of follow-up and in 40 patients treated with RFA for 
benign thyroid nodules. In the that study, both the Physical 
Component Summary and the Mental Component Summary 
significantly improved after one year, and remained stable 
from year one to year two. 
Our group recently published a study on changes in 
QoL, as assessed by means of ThyPRO after RFA of benign 
thyroid nodules. In that study, we did not find a significant 
improvement in ThyPRO scales, except for the “general 
score,” which improved after three months (32). The cause 
of less improvement of ThyPRO scales in this study (32) was 
probably induced by low volume reduction: the majority 
of patients showed less than a 50% volume reduction. 
Moreover, four patients showed increased nodule volume 
after RFA. The mean volume reductions of nodule was -18 
± 18%, -30 ± 24% and -27 ± 22% after RFA vs. -37 ± 23%, 
-53 ± 25% and -58 ± 25% in LA at 1, 6, and 12 months, 
respectively, although the features of nodules and inclusion 
criteria were the same in the two studies. In the present 
study, scores on the “goiter symptoms” and “general score” 
scales of the ThyPRO questionnaire showed a significant 
improvement from the first month and from sixth month 
onwards, respectively. The mean values of the scores on all 
13 scales displayed a significant reduction from the sixth 
month onwards. In the present study, scores on each of 
the other scales did not change significantly. This could 
be due to LA does not affecting thyroid function. Indeed, 
changes in hyperthyroid symptoms, hypothyroid symptoms, 
eye symptoms, tiredness, cognitive problems, anxiety, 
depression and emotional susceptibility scales could be 
more closely related to changes in thyroid hormonal status. 
Our study yielded more short-term data on changes in 
QoL than that of Valcavi et al. (31). However, our cohort of 
patients was smaller and follow-up was shorter.
The main limitation of our study is its small population 
(n = 14) and short follow-up. Further studies, especially in 
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a larger cohort of patients and over several years of follow-
up, are necessary in order to confirm or disprove our data.
In conclusion, LA is effective in reducing both nodule 
volume and neck symptoms. Moreover, the procedure is safe. 
In comparison to surgery, adverse events are few and mild. 
LA is well-tolerated by patients and the VAS score improves 
significantly in all patients. In our cohort of patients, 
the goiter scale, the general score and the mean value of 
ThyPRO scores improved significantly a few months after LA 
for benign non-functioning thyroid nodules.
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